U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
Morning Star,
U.S. FDA Approves BRAFTOVI ® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAF V600E -Mutant Metastatic…